Literature DB >> 22636800

Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.

Satsuki Mochizuki1, Kenji Soejima, Masayuki Shimoda, Hitoshi Abe, Aya Sasaki, Hirotaka James Okano, Hideyuki Okano, Yasunori Okada.   

Abstract

BACKGROUND: A disintegrin and metalloproteinase 28 (ADAM28) is implicated in tumor growth and metastasis in human breast and non-small cell lung carcinomas. We explored the mechanism of ADAM28-mediated metastasis by searching for new substrates of ADAM28.
METHODS: We used a yeast two-hybrid system to screen the human lung cDNA library for ADAM28-binding proteins and identified von Willebrand factor (VWF) as a potential candidate. Binding was confirmed using yeast two-hybrid and protein binding assays, and ADAM28-mediated cleavage of VWF was analyzed by immunoblotting. Exogenous VWF-induced apoptosis in vitro was examined in human lung carcinoma (PC-9 and Calu-3), breast carcinoma (MDA-MB231 and MCF-7), renal cell carcinoma (Caki-2 and 769P), and hepatocellular carcinoma (HepG2) cells, and expression of ADAM28 was assessed by reverse transcription-polymerase chain reaction and immunoblotting. Effect on lung metastasis of PC-9 and MDA-MB231 cells was assessed by knockdown of ADAM28 expression using short hairpin RNAs (ADAM28-shRNA) and small interfering RNAs (ADAM28-siRNA), and inhibition of activity using neutralizing anti-ADAM28 antibody, in a mouse xenograft model by in vivo imaging (n = 9 mice per group). All statistical tests were two-sided.
RESULTS: ADAM28 could bind to and cleave native VWF. Cells with very low ADAM28 expression (MCF-7, 769P, and HepG2) were susceptible to VWF-induced apoptosis, whereas cells with high expression (PC-9, Calu-3, MDA-MB231, and Caki-2) were resistant. Knockdown of ADAM28 expression in PC-9 and MDA-MB231 cells by shRNA showed increased carcinoma cell apoptosis mainly in lung blood vessels and statistically significantly decreased lung metastasis at week 3 after injection (PC-9-control [n = 9 mice] vs PC-9-ADAM28-shRNA [n = 9 mice]: mean count = 198 × 10(6) vs 37 × 10(6) photons/s, difference = 161 × 10(6) photons/s, 95% confidence interval = 134 × 10(6) to 188 × 10(6) photons/s, P < .001). Similar inhibition of lung metastasis was observed with ADAM28-siRNA and anti-ADAM28 antibody.
CONCLUSION: ADAM28 cleaves and inactivates proapoptotic VWF in carcinoma cells and enhances lung metastasis probably by promoting carcinoma cell survival within the blood vessels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22636800     DOI: 10.1093/jnci/djs232

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  29 in total

1.  New wrinkle between cancer and blood coagulation: metastasis and cleavage of von Willebrand factor by ADAM28.

Authors:  Stanley Zucker; Jian Cao
Journal:  J Natl Cancer Inst       Date:  2012-05-25       Impact factor: 13.506

2.  Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer: Potential use of Perioperative Desmopressin to Reduce Allogenic Blood Transfusion Rates.

Authors:  Juan Garona; Natasha T Sobol; Daniel F Alonso
Journal:  J Gastrointest Surg       Date:  2017-08-24       Impact factor: 3.452

3.  Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.

Authors:  Renyong Guo; Jiezuan Yang; Xia Liu; Jianping Wu; Yu Chen
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

4.  Enhancer RNA and NFκB-dependent P300 regulation of ADAMDEC1.

Authors:  Lihua Shi; Song Li; Kelly Maurer; Zhe Zhang; Michelle Petri; Kathleen E Sullivan
Journal:  Mol Immunol       Date:  2018-10-20       Impact factor: 4.407

5.  Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.

Authors:  Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

6.  Cirrhosis, von Willebrand Factor (vWF) and the Low Incidence of Metastatic Malignancy in Injured Liver.

Authors:  Daniel F Alonso
Journal:  Eurasian J Med       Date:  2015-10

Review 7.  The ADAMs family of proteases as targets for the treatment of cancer.

Authors:  Maeve Mullooly; Patricia M McGowan; John Crown; Michael J Duffy
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

Review 8.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

9.  von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.

Authors:  Hiroaki Takaya; Hideto Kawaratani; Yuki Tsuji; Keisuke Nakanishi; Soichiro Saikawa; Shinya Sato; Yasuhiko Sawada; Kosuke Kaji; Yasushi Okura; Naotaka Shimozato; Mitsuteru Kitade; Takemi Akahane; Kei Moriya; Tadashi Namisaki; Akira Mitoro; Masanori Matsumoto; Hiroshi Fukui; Hitoshi Yoshiji
Journal:  United European Gastroenterol J       Date:  2018-05-25       Impact factor: 4.623

10.  A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.

Authors:  Ruth S Weinberg; Marcelo O Grecco; Gimena S Ferro; Debora J Seigelshifer; Nancy V Perroni; Francisco J Terrier; Analía Sánchez-Luceros; Esteban Maronna; Ricardo Sánchez-Marull; Isabel Frahm; Marcelo D Guthmann; Daniela Di Leo; Eduardo Spitzer; Graciela N Ciccia; Juan Garona; Marina Pifano; Ana V Torbidoni; Daniel E Gomez; Giselle V Ripoll; Roberto E Gomez; Ignacio A Demarco; Daniel F Alonso
Journal:  Springerplus       Date:  2015-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.